A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization

STUDY QUESTION: Is oral dydrogesterone 30 mg daily (10 mg three times daily [TID]) non-inferior to micronized vaginal progesterone (MVP) 600 mg daily (200 mg TID) for luteal support in in vitro fertilization (IVF), assessed by the presence of fetal heartbeats determined by transvaginal ultrasound at...

Descripción completa

Detalles Bibliográficos
Autores principales: Tournaye, Herman, Sukhikh, Gennady T., Kahler, Elke, Griesinger, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400051/
https://www.ncbi.nlm.nih.gov/pubmed/28333318
http://dx.doi.org/10.1093/humrep/dex023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400051/
https://www.ncbi.nlm.nih.gov/pubmed/28333318
http://dx.doi.org/10.1093/humrep/dex023

Ejemplares similares